Description
Vorbipiprant is a prostaglandin E2 (PGE2) receptor antagonist used in cancer treatment to enhance immune system response against tumors. The drug works by blocking PGE2 signaling pathways that normally suppress immune function in the tumor microenvironment. It is designed to improve the effectiveness of other cancer immunotherapies by reducing immunosuppressive signals.
Mechanism of Action
Blocks prostaglandin E2 receptors (EP2 and EP4) to reduce tumor-associated immunosuppression and enhance T-cell activation and proliferation in the tumor microenvironment.
Side Effects
Gastrointestinal upset
Fatigue
Headache
Potential cardiovascular effects
And immune-related adverse events when used in combination with other immunotherapies.
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT05845450
med_phase_prefix2
Recruiting
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Italy